title: Synthesis and anticancer activity of certain mononuclear Ru (II) complexes.
abstract: Bis(1,10-phenanthroline/2,2'-bipyridine) ruthenium(II)complexes containing TCP, TTZ OPBI, and BTSC ligands (where, TCP = 1-thiocarbamoyl-3,5-diphenyl-2-pyrazoline, TTZ = 2-(3,5-diphenyl-4,5-dihydropyrazol-1-yl)-4-phenylthiazole, OPBI = 2-hydroxyphenyl benzimidazole and BTSC = benzoin thiosemicarbazone) have been prepared and characterized. The spectral data suggested that the ligands were coordinated with the metal through nitrogen, sulfur and oxygen atoms. The target complexes were tested in vivo for anticancer activity against transplantable murine tumor cell line, Ehrlich's Ascitic Carcinoma (EAC). All these complexes increased the life span of the EAC-bearing mice, decreased their tumor volume and viable ascitic cell count as well as improved Hb, RBC and WBC counts. These results suggest that the Ru(II) complexes exhibit significant antitumor activity in EAC-bearing mice. It was also observed that the ruthenium complexes protected red blood cells from 2,2'-azo-bis(2-methylpropionamidine) dihydrochloride (AAPH)- induced hemolysis. The inhibitory effect was dose-dependent at a concentration of 20-120 microg/ml.
authors.affiliation: Division of Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India. suresh_dna@yahoo.co.in
authors.forename: Suresh
authors.initials: S
authors.lastname: Rathinasamy
authors.forename: Subhas Somalingappa
authors.initials: SS
authors.lastname: Karki
authors.forename: Shiladitya
authors.initials: S
authors.lastname: Bhattacharya
authors.forename: Lakshmanan
authors.initials: L
authors.lastname: Manikandan
authors.forename: Senthilkumar G
authors.initials: SG
authors.lastname: Prabakaran
authors.forename: Malaya
authors.initials: M
authors.lastname: Gupta
authors.forename: Upal Kanti
authors.initials: UK
authors.lastname: Mazumder
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000473:pathology; D045744:Cell Line, Tumor; D008297:Male; D051379:Mice; D015394:Molecular Structure; D017975:Ruthenium Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D017975:Ruthenium Compounds